Eli Lilly, Roche, GSK, and Merck are committing billions of dollars to artificial intelligence partnerships and infrastructure. These companies are building powerful supercomputers with Nvidia to address high failure rates in drug development.
Current AI gains emerge from operational enhancements and manufacturing acceleration rather than research breakthroughs. Eli Lilly implemented a digital twin of its manufacturing process to optimize efficiency and scale production.
While the long-term goal is to revolutionize drug discovery, AI has not yet definitively improved clinical trial success rates.